Oxocrebanine inhibits the proliferation of hepatocellular carcinoma cells by promoting apoptosis and autophagy

Figure 4 Protein expression levels of Bcl-2, Bax, Bak, and Mcl-1 in Hep3B2. 1-7 cells. A: Western blot analysis of Bcl-2 protein level in Hep3B2.1-7 cells after treatment with oxocrebanine. VP16 (32.54 μmol/L) was used as a control; B: Western blot analysis of Bax protein level in Hep3B2.1-7 cells after treatment with oxocrebanine, with VP16 (32.54 μmol/L) used as a control; C: Western blot analysis data indicated that the ratio of Bcl-2 to Bax protein expression was decreased with oxocrebanine treatments; D: Level of Bak in Hep3B2.1-7 cells after treatment with oxocrebanine. VP16 (32.54 μmol/L) was used as a control; E: Western blot analysis data showed that the expression of Bak was downregulated by oxocrebanine treatments; F: Level of Mcl-1 in Hep3B2.1-7 cells after treatment with oxocrebanine. VP16 (32.54 μmol/L) was used as a control; G: Western blot analysis data showed that the expression of Mcl-1 was downregulated by oxocrebanine treatments. Data are shown as the mean ± SD. ^aP < 0.01 vs control (n = 3).